Paradigm and Daraxonrasib in NSCLC

OncoPharm by OncoPharmPod

PARADIGM is finally published, so we have more details from this study presented at ASH about HMA/Ven vs. Intensive Chemo if fit patients with AML. Daraxonrasib looks like a promising drug for RAS-mutant NSCLC, too. Down...View more